## UNH: UnitedHealth Group Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.25 indicates fundamental undervaluation. Quality metrics strong (ROE 18%). Caution: momentum weakening (-6.0% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($308.06)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. UnitedHealth Group Outlines Action Plans For Operational Improvement Following Independent Audits**
- Source: Word & Brown General Agency | 20251223T210837 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group has published the results of independent audits focusing on risk assessments in Medicare Advantage, care services management, and Optum Rx's drug manufacturer discount policies. The audits, conducted by FTI Consulting Inc. and Analysis Group Inc., generally showed positive results but highlighted instances where UnitedHealthcare failed to address prior regulatory audit flags. In response, UHG has outlined 23 action plans to enhance transparency and operational efficiency, including annual policy reviews, new governance for Optum's HouseCalls program, and streamlining processes at Optum Rx.

**2. Yousif Capital Management LLC Lowers Stock Holdings in UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251223T140815 | Somewhat-Bullish | Relevance: 100%
- Yousif Capital Management LLC reduced its stake in UnitedHealth Group (NYSE: UNH) by 4.1% in the third quarter, selling 4,138 shares and ending with 95,894 shares valued at $33.11 million. Despite this, several brokerages have raised price targets for UNH, although the consensus analyst rating remains a "Hold" with an average price target of $385.54. The company slightly exceeded EPS estimates and reported a 12.2% year-over-year revenue increase, along with declaring a quarterly dividend.

**3. UnitedHealth Group (UNH) Stock News, Forecasts and Analysis for Dec. 22, 2025: Independent Reviews, DOJ Scrutiny, and 2026 Guidance in Focus**
- Source: ts2.tech | 20251222T190905 | Somewhat-Bearish | Relevance: 100%
- UnitedHealth Group (UNH) is under investor scrutiny as it faces independent operational reviews, Department of Justice investigations, and prepares to release its 2026 guidance. The company's stock, trading around $325, reflects a careful balance between a potential recovery driven by operational fixes and risks from regulatory pressures and medical-cost volatility. Investors are keenly awaiting the January 27, 2026 earnings call for clarity on the company's future direction and earnings power.

**4. Where is UnitedHealth Group (UNH) Headed According to Wall Street?**
- Source: Finviz | 20251221T150252 | Somewhat-Bullish | Relevance: 100%
- UnitedHealth Group (UNH) is undergoing significant operational changes following audits of its health services and pharmacy benefit units, aiming for increased automation and standardization. The CEO, Stephen Hemsley, has committed to a comprehensive examination of key policies and processes, with many action plans expected to be finalized by Q1 2026. Additionally, Optum Rx is modernizing pharmacy reimbursements, with 100% of community and independent pharmacies in its network now using a new cost-based contract model.

**5. Coho Partners Ltd. Sells 65,677 Shares of UnitedHealth Group Incorporated $UNH**
- Source: MarketBeat | 20251223T100827 | Somewhat-Bullish | Relevance: 100%
- Coho Partners Ltd. reduced its stake in UnitedHealth Group (UNH) by 42.9% in Q3, selling 65,677 shares but retaining a significant holding. UnitedHealth Group exceeded quarterly EPS estimates, with revenue up 12.2% year-over-year, and has a market capitalization nearing $294.9 billion, supported by institutional investors and a mixed analyst outlook. The company also declared a quarterly dividend of $2.21 per share.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 23 ($0.00M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (-0.3%)
- Blackrock Inc.: 8.2% (-1.4%)
- State Street Corpora: 4.9% (-1.8%)
- JPMORGAN CHASE & CO: 4.1% (+85.6%)
- Geode Capital Manage: 2.4% (+2.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.0% 5d) with bearish MACD, trend may be turning.
2. Long-term trend broken: trading 8.1% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.25 suggests fair value with growth premium. Forward P/E 18.3x stretched relative to 9% growth. Balance sheet: $5.1B free cash flow. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $294.2B |
| Beta | 0.43 |
| 52W Range | $234.60 - $606.36 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.25 |
| Forward P/E | 18.3 |
| Current P/E | 19.9 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.6% to -2.4% (-6.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >4.0% for momentum thesis). Below SMA200 (0.92x), long-term trend not supportive. RSI neutral at 44. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.40% (CS: 28) | Weak |
| RSI_14 | 44.5 | Neutral |
| MACD Histogram | -0.33 | Bearish |
| vs SMA20 | 0.983x | Below |
| vs SMA50 | 0.966x | Below |
| vs SMA200 | 0.919x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $324.66
- **Stop Loss:** $308.06 (5.1% risk)
- **Target:** $357.86 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 72
- **Position Value:** $23,375.52
- **Portfolio %:** 23.38%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-01-15 (Est: $2.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.81 | $2.92 | +4.0% |
| 2025Q2 | $4.45 | $4.08 | -8.2% |
| 2025Q1 | $7.29 | $7.20 | -1.3% |
| 2024Q4 | $6.74 | $6.81 | +1.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*